ALF unveils network to connect living donors with strangers in need
The American Liver Foundation (ALF) is launching a first-of-its kind national database, called the ALF Living Donor Network, to connect people willing to…
News
Drug combo shrinks liver fat in rats and zebrafish: Study
A combination of pemafibrate and telmisartan, two medications approved in some countries to help manage cardiovascular conditions, may help reduce the buildup of liver fat…
Know your risks – and options – this National Liver Awareness Month
October is National Liver Awareness Month and Liver Cancer Awareness Month, and advocacy organizations across the U.S., including the American Liver Foundation (ALF), are…
Enrollment complete in 2 Phase 2 trials testing hepatitis B treatment
Enrollment is complete in two Phase 2 clinical trials testing Ausperbio’s AHB-137 in people with chronic hepatitis B, the company said. That “positions us…
PBC worst for life quality among autoimmune liver diseases: Study
Adults with autoimmune liver disease experience lower quality of life, especially those with primary biliary cholangitis (PBC), who report more fatigue, sleepiness, and pain…
PFIC Awareness Day means… spotlighting the rare liver disease
Supporters are gearing up for the 7th Annual PFIC Awareness Day on Oct. 5, with advocates behind the yearly event focused on improving public awareness,…
High blood pressure may pose greatest risk of death in MASLD
High blood pressure is a leading cardiometabolic risk factor — a condition linked to problems such as heart disease, stroke, and diabetes — associated with…
7 genes identified as potential biliary atresia treatment targets
Researchers identified seven genes that may contribute to biliary atresia, a discovery that could provide opportunities to develop treatments or biological markers for the…
Program improves hepatitis C treatment access for new moms
A simple shift in where new mothers receive care is helping the fight against hepatitis C. By bringing infectious disease specialists to a mother’s…
Phase 2 trial of volixibat for PSC-related itching now fully enrolled
Enrollment is complete in the Phase 2b VISTAS clinical trial, which is testing the experimental oral treatment volixibat in people with itching due to…
Recent Posts
- A new tool may help predict your future with liver disease
- ALF unveils network to connect living donors with strangers in need
- Drug combo shrinks liver fat in rats and zebrafish: Study
- Know your risks – and options – this National Liver Awareness Month
- Enrollment complete in 2 Phase 2 trials testing hepatitis B treatment